ODR 014 – UnBurnable Series

ODR 014 – UnBurnable Series

Hi Scott, Thank you for adding this kind of content to your platform. This Unburnable episode has prompted me to comment on a topic close to my heart. You spoke about inner voice and thinking in visual imagery. There are some interesting cognitive differences that can occur in these areas that are important to know…

Read More
EMCrit RACC-Lit Review – June 2025

EMCrit RACC-Lit Review – June 2025

Cite this post as: Scott Weingart, MD FCCM. EMCrit RACC-Lit Review – June 2025. EMCrit Blog. Published on June 30, 2025. Accessed on July 29th 2025. Available at [https://emcrit.org/emcrit/emcrit-racc-lit-review-june-2025/ ]. Financial Disclosures: The course director, Dr. Scott D. Weingart MD FCCM, reports no relevant financial relationships with ineligible companies. This episode’s speaker(s) report no relevant…

Read More
Critical Care Evidence Updates – May 2025 – The Bottom Line

Critical Care Evidence Updates – May 2025 – The Bottom Line

Randomised Controlled Trials A Multinational Randomized Trial of Mega-Dose Esomeprazole As Anti-Inflammatory Agent in Sepsis  Critical Care Medicine A pilot multicenter randomized controlled trial on individualized blood pressure targets versus standard care among critically ill patients with shock  Journal of Intensive Care A randomised, controlled, feasibility trial comparing vasopressors infused via peripheral cannula versus central…

Read More
Emergency Evidence Updates – May 2025 – The Bottom Line

Emergency Evidence Updates – May 2025 – The Bottom Line

Randomised Controlled Trials A non-inferiority randomised controlled trial of a Shorter Acetylcysteine Regimen for Paracetamol Overdose – the SARPO trial.  Journal of Hepatology Association of central capillary refill time with mortality in adult trauma patients: a secondary analysis of the crash-2 randomised controlled trial data  Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine Dorsal Digital…

Read More
Efficacy and Safety in a Phase 3 Trial

Efficacy and Safety in a Phase 3 Trial

What was it? Multicentre, double-blind, placebo-controlled phase 3 trial (TESTS), evaluating whether thymosin α1, animmunomodulatory drug, reduces 28-day all-cause mortality in adults with sepsis, conducted across 22 centresin China from September 2016 to December 2020. The Devil in the details! 1,106 adults (18–85 years) with sepsis per Sepsis-3 criteria, randomised 1:1 to thymosin α1 (n=552) or placebo (n=554), with 1,089 included in modified intention-to-treat analysis (thymosin α1: n=542, placebo: n=547). Subcut thymosin α1 (1.6 mg) vs placebo ‘lyophilised saline’ twice daily for 7 days (unless discontinued due to either discharge from…

Read More
Revolutionizing Echocardiography: PanEcho’s AI Insights

Revolutionizing Echocardiography: PanEcho’s AI Insights

What was it? Multi-center, retrospective study evaluating PanEcho, an AI system using multitask deep learning to automate interpretation of transthoracic echocardiography (TTE) across 39 labels and measurements on transthoracic echocardiography (TTE). The Devil in the Details! Data: 1,193,876 echocardiographic videos from 32,265 TTE studies (24,405 patients) at Yale-New Haven Health System (YNHHS), 2016–2022. Design: PanEcho,…

Read More
Training an ECPR Cannulator Army with Joe Bellezzo

Training an ECPR Cannulator Army with Joe Bellezzo

Podcast: Play in new window | Download (Duration: 38:35 — 29.9MB) Subscribe: RSS Is it better to rely on a few highly trained specialists—or an army of less experienced proceduralists? In this episode, Joe Bellezzo and Zack Shinar delve into the evolution of ECPR (Extracorporeal Cardiopulmonary Resuscitation), exploring the pros and cons of each cannulation…

Read More